1
|
Nedić O, Penezić A, Minić S, Radomirović M, Nikolić M, Ćirković Veličković T, Gligorijević N. Food Antioxidants and Their Interaction with Human Proteins. Antioxidants (Basel) 2023; 12:antiox12040815. [PMID: 37107190 PMCID: PMC10135064 DOI: 10.3390/antiox12040815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 03/22/2023] [Accepted: 03/25/2023] [Indexed: 03/29/2023] Open
Abstract
Common to all biological systems and living organisms are molecular interactions, which may lead to specific physiological events. Most often, a cascade of events occurs, establishing an equilibrium between possibly competing and/or synergistic processes. Biochemical pathways that sustain life depend on multiple intrinsic and extrinsic factors contributing to aging and/or diseases. This article deals with food antioxidants and human proteins from the circulation, their interaction, their effect on the structure, properties, and function of antioxidant-bound proteins, and the possible impact of complex formation on antioxidants. An overview of studies examining interactions between individual antioxidant compounds and major blood proteins is presented with findings. Investigating antioxidant/protein interactions at the level of the human organism and determining antioxidant distribution between proteins and involvement in the particular physiological role is a very complex and challenging task. However, by knowing the role of a particular protein in certain pathology or aging, and the effect exerted by a particular antioxidant bound to it, it is possible to recommend specific food intake or resistance to it to improve the condition or slow down the process.
Collapse
Affiliation(s)
- Olgica Nedić
- Institute for the Application of Nuclear Energy, Department for Metabolism, University of Belgrade, Banatska 31b, 11080 Belgrade, Serbia
- Correspondence:
| | - Ana Penezić
- Institute for the Application of Nuclear Energy, Department for Metabolism, University of Belgrade, Banatska 31b, 11080 Belgrade, Serbia
| | - Simeon Minić
- Center of Excellence for Molecular Food Sciences, Department of Biochemistry, Faculty of Chemistry, University of Belgrade, 11000 Belgrade, Serbia
| | - Mirjana Radomirović
- Center of Excellence for Molecular Food Sciences, Department of Biochemistry, Faculty of Chemistry, University of Belgrade, 11000 Belgrade, Serbia
| | - Milan Nikolić
- Center of Excellence for Molecular Food Sciences, Department of Biochemistry, Faculty of Chemistry, University of Belgrade, 11000 Belgrade, Serbia
| | - Tanja Ćirković Veličković
- Center of Excellence for Molecular Food Sciences, Department of Biochemistry, Faculty of Chemistry, University of Belgrade, 11000 Belgrade, Serbia
- Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11000 Belgrade, Serbia
| | - Nikola Gligorijević
- Institute for the Application of Nuclear Energy, Department for Metabolism, University of Belgrade, Banatska 31b, 11080 Belgrade, Serbia
| |
Collapse
|
2
|
Jourdi G, Abdoul J, Siguret V, Decleves X, Frezza E, Pailleret C, Gouin-Thibault I, Gandrille S, Neveux N, Samama CM, Pasquali S, Gaussem P. Induced forms of α 2-macroglobulin neutralize heparin and direct oral anticoagulant effects. Int J Biol Macromol 2021; 184:209-217. [PMID: 34126147 DOI: 10.1016/j.ijbiomac.2021.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/07/2021] [Accepted: 06/08/2021] [Indexed: 10/21/2022]
Abstract
Alpha2-macroglobulin (α2M) is a physiological macromolecule that facilitates the clearance of many proteinases, cytokines and growth factors in human. Here, we explored the effect of induced forms of α2M on anticoagulant drugs. Gla-domainless factor Xa (GDFXa) and methylamine (MA)-induced α2M were prepared and characterized by electrophoresis, immunonephelometry, chromogenic, clot waveform and rotational thromboelastometry assays. Samples from healthy volunteers and anticoagulated patients were included. In vivo neutralization of anticoagulants was evaluated in C57Bl/6JRj mouse bleeding-model. Anticoagulant binding sites on induced α2M were depicted by computer-aided energy minimization modeling. GDFXa-induced α2M neutralized dabigatran and heparins in plasma and whole blood. In mice, a single IV dose of GDFXa-induced α2M following anticoagulant administration significantly reduced blood loss and bleeding time. Being far easier to prepare, we investigated the efficacy of MA-induced α2M. It neutralized rivaroxaban, apixaban, dabigatran and heparins in spiked samples in a concentration-dependent manner and in samples from treated patients. Molecular docking analysis evidenced the ability of MA-induced α2M to bind non-covalently these compounds via some deeply buried binding sites. Induced forms of α2M have the potential to neutralize direct oral anticoagulants and heparins, and might be developed as a universal antidote in case of major bleeding or urgent surgery.
Collapse
Affiliation(s)
- Georges Jourdi
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; AP-HP. Centre-Université de Paris, Hôpital Cochin, F-75014, Paris, France; Research Centre, Montreal Heart Institute, University of Montreal, Faculty of Pharmacy, Montreal, Canada.
| | - Johan Abdoul
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France
| | - Virginie Siguret
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; AP-HP. Nord-Université de Paris, Hôpital Lariboisière, F-75010 Paris, France
| | - Xavier Decleves
- AP-HP. Centre-Université de Paris, Hôpital Cochin, F-75014, Paris, France; Université de Paris, Variabilité de réponse aux psychotropes, INSERM UMR_S1144, F-75006 Paris, France
| | - Elisa Frezza
- Laboratoire CiTCoM, Université de Paris, CNRS, F-75006 Paris, France
| | - Claire Pailleret
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; Clinique du Mont Louis, F-75011 Paris, France
| | - Isabelle Gouin-Thibault
- Laboratoire d'hématologie, CHU Pontchaillou, Université de Rennes 1, CIC-Inserm1414, F-35000 Rennes, France
| | - Sophie Gandrille
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; AP-HP. Centre-Université de Paris, Hôpital Européen Georges Pompidou, F-75015 Paris, France
| | - Nathalie Neveux
- AP-HP. Centre-Université de Paris, Hôpital Cochin, F-75014, Paris, France
| | - Charles Marc Samama
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; AP-HP. Centre-Université de Paris, Hôpital Cochin, F-75014, Paris, France
| | - Samuela Pasquali
- Laboratoire CiTCoM, Université de Paris, CNRS, F-75006 Paris, France
| | - Pascale Gaussem
- Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S1140, F-75006, Paris, France; AP-HP. Centre-Université de Paris, Hôpital Européen Georges Pompidou, F-75015 Paris, France.
| |
Collapse
|